ADMA BIOLOGICS INC (ADMA)

US0008991046 - Common Stock

12.31  +0.31 (+2.58%)

After market: 12.44 +0.13 (+1.06%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADMA BIOLOGICS INC

NASDAQ:ADMA (7/11/2024, 7:00:00 PM)

After market: 12.44 +0.13 (+1.06%)

12.31

+0.31 (+2.58%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month146.69%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap2.85B
Shares
PEN/A
Fwd PE22.35
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADMA Daily chart

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 617 full-time employees. The company went IPO on 2013-10-17. The company develops, manufactures, and markets specialty plasma-derived biologics for the treatment and prevention of infectious diseases. The company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product includes BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates over 10 source plasma collection facilities in the United States. Its Plasma Collection Centers segment provides a portion of its blood plasma for the manufacture of its products.

Company Info

ADMA BIOLOGICS INC

C/O Adma Biologics, Inc., 465 State Route 17

Ramsey NEW JERSEY 07446

P: 12014785552

CEO: Adam S. Grossman

Employees: 617

Website: https://www.admabiologics.com/

ADMA News

News Image16 hours ago - InvestorPlaceBull Run Alert: 3 Stocks Set to Soar in the Coming Months

Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns.

News Image14 days ago - Investor's Business DailyUroGen Pharma Stock Earns 91 RS Rating

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

News Image20 days ago - Investor's Business DailyArcellx Stock Earns Relative Strength Rating Upgrade

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

News Image21 days ago - Investor's Business DailyIntra-Cellular Therapies Stock Scores RS Rating Upgrade To 87

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

News Imagea month ago - Investor's Business DailyNeurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Earns RS Rating Upgrade

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

ADMA Twits

Here you can normally see the latest stock twits on ADMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example